Literature DB >> 6103267

Classification of spinal muscular atrophies.

J Pearn.   

Abstract

Clinical heterogeneity within the spinal muscular atrophies (SMA) has long been a source of confusion for questions of prognosis and genetic counselling. Comprehensive clinical and genetic analyses of 240 consecutive index cases from two English centres (The English SMA Study) have enabled some nosological questions to be resolved. The different SMA syndromes can be discriminated by (a) age at the first clinical signs of the disease, (b) pattern of muscle involvement, (c) age at death of other patients within an affected kindred, and (d) genetic evidence. Seven different SMA syndromes can be defined clinically and genetically; thirteen mutant genes are incriminated. Prevalence and incidence figures are presented. SMA type I (Werdnig-Hoffman disease) and chronic childhood SMA together comprise 74% of all SMA cases. The classification of the spinal muscular atrophies presented also provides the differential diagnosis for newly presenting cases.

Entities:  

Mesh:

Year:  1980        PMID: 6103267     DOI: 10.1016/s0140-6736(80)90847-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  126 in total

1.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

Authors:  B Schrank; R Götz; J M Gunnersen; J M Ure; K V Toyka; A G Smith; M Sendtner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Prenatal prediction of Werdnig-Hoffmann disease using linked polymorphic DNA probes.

Authors:  J Melki; S Abdelhak; P Burlet; V Raclin; J Kaplan; R Spiegel; S Gilgenkrantz; N Philip; M L Chauvet; Y Dumez
Journal:  J Med Genet       Date:  1992-03       Impact factor: 6.318

Review 4.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

5.  Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein.

Authors:  M D Hebert; P W Szymczyk; K B Shpargel; A G Matera
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

6.  Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis.

Authors:  D W Parsons; P E McAndrew; P S Allinson; W D Parker; A H Burghes; T W Prior
Journal:  J Med Genet       Date:  1998-08       Impact factor: 6.318

7.  Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings.

Authors:  Rebecca Hurst Davis; Barbara J Godshall; Erin Seffrood; Mary Marcus; Bernard A LaSalle; Brenda Wong; Mary K Schroth; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-10-04       Impact factor: 1.987

8.  Prospective study of gross motor development in children with SMA type II.

Authors:  R Bono; M Inverno; G Botteon; E Iotti; M Estienne; A Berardinelli; G Lanzi; E Fedrizzi
Journal:  Ital J Neurol Sci       Date:  1995-05

Review 9.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

10.  Single-sperm analysis for recurrence risk assessment of spinal muscular atrophy.

Authors:  Philippe Burlet; Nadine Gigarel; Maryse Magen; Séverine Drunat; Alexandra Benachi; Laetitia Hesters; Arnold Munnich; Jean-Paul Bonnefont; Julie Steffann
Journal:  Eur J Hum Genet       Date:  2009-11-11       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.